Identification of novel bio-marker associated with drug response in ovarian cancer
| Project/Area Number |
24592529
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NISHIO Kazuto 近畿大学, 医学部, 教授 (10208134)
AKAHANE Tomoko 慶應義塾大学, 医学部, 助教 (40398699)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
|
|---|
| Keywords | 卵巣癌 / 分子標的治療薬 / 化学療法 / バイオマーカー / SNP / コピー数増幅 / FGF3 / FGF4 / TC療法 / 効果予測 / copy number polymorphism / 分子標的治療 |
|---|
| Outline of Final Research Achievements |
The aims are to clarify 1) the method for predicting effect of postoperative chemotherapy by single nucleotide polymorphism(SNP) and 2) the bio-marker for predicting effect of targeted therapy for ovarian cancer.
1)Global SNP annalysis using normal lymphocytes from ovarian cancer patients on the basis of a degree of neutropenia following adjuvant chemotherapy extracted five SNPs and discriminant analysis extracted twenty SNPs. Some of these SNPs correlated with the prognosis. 2) Copy number amplification of FGF3 and FGF4 was detected in 7% and 12% of ovarian cancer tissues and ES2 cell line. IC50 of sorafenib were significantly lower in ES2 cell line than that in the other ovarian cancer cell lines.
|
Report
(4 results)
Research Products
(6 results)
